396 related articles for article (PubMed ID: 29153851)
21. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
[TBL] [Abstract][Full Text] [Related]
22. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
Sawyer SL; Emerman M; Malik HS
PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
[TBL] [Abstract][Full Text] [Related]
23. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
Doehle BP; Schäfer A; Cullen BR
Virology; 2005 Sep; 339(2):281-8. PubMed ID: 15993456
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
Zennou V; Bieniasz PD
Virology; 2006 May; 349(1):31-40. PubMed ID: 16460778
[TBL] [Abstract][Full Text] [Related]
25. Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.
Mohammadzadeh N; Love RP; Gibson R; Arts EJ; Poon AFY; Chelico L
Heliyon; 2019 Apr; 5(4):e01498. PubMed ID: 31025011
[TBL] [Abstract][Full Text] [Related]
26. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
27. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
28. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
29. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
30. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
31. Anti-HIV Activities and Mechanism of 12-O-Tricosanoylphorbol-20-acetate, a Novel Phorbol Ester from Ostodes katharinae.
Chen H; Zhang R; Luo RH; Yang LM; Wang RR; Hao XJ; Zheng YT
Molecules; 2017 Sep; 22(9):. PubMed ID: 28885587
[TBL] [Abstract][Full Text] [Related]
32. Protein interaction map of APOBEC3 enzyme family reveals deamination-independent role in cellular function.
Jang GM; Sudarsan AKA; Shayeganmehr A; Munhoz EP; Lao R; Gaba A; Rodríguez MG; Love RP; Polacco BJ; Zhou Y; Krogan NJ; Kaake RM; Chelico L
bioRxiv; 2024 Feb; ():. PubMed ID: 38370690
[TBL] [Abstract][Full Text] [Related]
33. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination.
Lackey L; Law EK; Brown WL; Harris RS
Cell Cycle; 2013 Mar; 12(5):762-72. PubMed ID: 23388464
[TBL] [Abstract][Full Text] [Related]
34. Further investigation of simian immunodeficiency virus Vif function in human cells.
Gaddis NC; Sheehy AM; Ahmad KM; Swanson CM; Bishop KN; Beer BE; Marx PA; Gao F; Bibollet-Ruche F; Hahn BH; Malim MH
J Virol; 2004 Nov; 78(21):12041-6. PubMed ID: 15479843
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
37. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
[TBL] [Abstract][Full Text] [Related]
38. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
Russell RA; Wiegand HL; Moore MD; Schäfer A; McClure MO; Cullen BR
J Virol; 2005 Jul; 79(14):8724-31. PubMed ID: 15994766
[TBL] [Abstract][Full Text] [Related]
39. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
